Immunosuppressant Combined With Pirfenidone in CTD-ILD
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
A prospective cohort study was used to observe the efficacy and safety of different
immunosuppressive agents with/wo pirfenidone on CTD-ILD patients in Qilu Hospital of Shandong
University for 36 months.The main research endpoints are lung function, patient dyspnea
score, 6-minute walking distance, imaging indicators, primary disease activity, adverse
reactions, etc.